Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Portage Biotech Inc. ("Portage" or "the Company" )) (OTC ... announce that the Company will be presenting  at the ... held in London, UK . Portage,s ... James Mellon , a director of Portage, will provide ... at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), and Biohaven ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
(Date:4/16/2015)... BURLINGAME, Calif. , April 16, 2015  Scientists ... session, "New Drugs on the Horizon," at the American ... Philadelphia, PA on Sunday, April 19, ... , Ph.D., Cleave,s Director of Biology, will present new ... CB-5083, a first-in-class, oral inhibitor of p97, a critical ...
(Date:4/16/2015)... Switzerland , April 16, ... part of Debiopharm Group ™ , a Swiss-based ... target unmet medical needs as well as ... on the investigational compounds Debio 1143 (SMAC mimetic) ... presented at the 2015 Annual meeting of ...
Breaking Biology Technology:Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
... of Pittsburgh School of Dental Medicine are piecing together ... to novel nanoscale approaches to developing biomaterials. The findings ... of the National Academy of Sciences . Dental ... and combines high hardness with resilience, said Elia Beniash, ...
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" ... focus on cell based therapeutics development, today announced that ... Program (PRMRP) of the Office of the Congressionally Directed ... be applied towards funding the Company,s VSEL™ Technology. This ...
... testing within the pharmaceutical and cosmetic industries and companies ... their products are safe to use. Research published in ... demonstrates that the response of laboratory grown human cells ... or non-sensitizing, and can even predict the strength of ...
Cached Biology Technology:NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 2NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 3NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 4Cell-based alternative to animal testing 2
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... An international consortium of scientists, including Universitat Autnoma ... genome of three species of parasitoid wasps of the ... information on the genetic mechanisms of evolution. It is ... pests and of insect-borne diseases, since parasitoid wasps bite ...
... American Recovery and Reinvestment Act (ARRA) the economic ... 100 examples of how a relatively small element of ... for the nation. Of the $787 billion contained ... and science infrastructure. ScienceWorksForUS, a coalition of three ...
... , PISCATAWAY, N.J. , Feb. 17 ... launch of a substantial upgrade to the IEEE Xplore ... interface and customizable search tools make exploring IEEE,s more than ... productive. Users can now spend less time researching and more ...
Cached Biology News:Genome sequencing of 3 parasitoid wasp species 2Universities highlight benefits of stimulus research funding 2Universities highlight benefits of stimulus research funding 3IEEE Launches Major Upgrade of IEEE Xplore(R) Digital Library 2IEEE Launches Major Upgrade of IEEE Xplore(R) Digital Library 3IEEE Launches Major Upgrade of IEEE Xplore(R) Digital Library 4
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Recombinant Rat CINC-2 alpha, CF...
sodium channel, nonvoltage-gated 1 alpha,...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
Biology Products: